Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localizing treatment to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] Clinical Pipeline - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in various EpCAM-expressing epithelial cancers, including colorectal cancer (CRC), and was developed in collaboration with ImmunoGen [3] - CX-801 is designed for broad applicability in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Management will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [2] - A live webcast of the presentations will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2]

Group 1 - CytomX Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference in London on November 20, 2025, at 9:00 a.m. GMT [1] - A live webcast of the presentation will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2] Group 2 - CytomX is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked biologics for cancer treatment [3] - The company’s PROBODY therapeutic platform aims to create safer and more effective therapies localized to the tumor microenvironment [3] - Current clinical-stage pipeline includes CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CytomX has established collaborations with major oncology leaders such as Amgen, Astellas, and Bristol Myers Squibb [3]

Core Insights - CytomX Therapeutics, Inc. will report its third quarter financial results on November 6, 2025, after U.S. market close [1] - A conference call and webcast will follow the announcement at 5:00 p.m. ET / 2:00 p.m. PT [1] Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated, masked biologics localized to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies [3] - Current clinical-stage pipeline includes CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in multiple EpCAM-expressing epithelial cancers, including colorectal cancer [3] - CX-801 is designed for use in both immuno-oncology sensitive and insensitive tumors [3] - CytomX has established collaborations with major oncology leaders such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]

Core Insights - CytomX Therapeutics has appointed Rachael Lester as Senior Vice President and Chief Business Officer to enhance its strategic long-term value creation and partnering strategy [1][2] - The company is well-positioned to advance its clinical assets, particularly CX-2051 and CX-801, which target high unmet medical needs in cancer treatment [2][4] Company Overview - CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked biologics aimed at localized tumor treatment [4] - The company's PROBODY therapeutic platform enables the creation of safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates, T-cell engagers, and immune modulators [4] Leadership Experience - Rachael Lester brings over 20 years of experience in corporate strategy and business development within the biopharmaceutical industry [3] - Prior to joining CytomX, she held significant roles at Replicate Bioscience and Harpoon Therapeutics, where she was instrumental in securing financing and establishing major partnerships [3] Clinical Pipeline - CytomX's lead clinical assets include CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine, both of which have broad potential across various cancer types [4] - CX-2051 is designed to treat multiple EpCAM-expressing epithelial cancers, including colorectal cancer, while CX-801 has applications in both immuno-oncology sensitive and insensitive tumors [4] Strategic Collaborations - The company has established strategic partnerships with leading oncology firms such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna to enhance its research and development efforts [4]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localized tumor treatment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM), and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] Upcoming Events - CytomX management will participate in several investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 4, 2025, with a fireside chat at 8:35 a.m. ET [2] - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, with a formal presentation at 11:30 a.m. ET [2] - Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, with a fireside chat at 1:05 p.m. ET [2] - A live webcast of the presentations will be available on CytomX's website, and management will be available for one-on-one meetings with registered investors [2]

Group 1 - CytomX Therapeutics, Inc. will report its second quarter financial results on August 7, 2025, after U.S. market close [1] - A conference call and webcast will follow the financial results announcement at 5:00 p.m. ET / 2:00 p.m. PT [1][2] - Participants can access the live webcast from CytomX's website and are advised to register at least 10 minutes prior to the call [2] Group 2 - CytomX is a clinical-stage biopharmaceutical company focused on developing conditionally activated biologics for cancer treatment [3] - The company's pipeline includes therapeutic candidates such as CX-2051, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CytomX has established collaborations with major oncology leaders including Amgen, Astellas, and Bristol Myers Squibb [3]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localized tumor treatment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies [3] - CytomX's pipeline includes therapeutic candidates such as CX-2051 and CX-801, targeting various cancer types [3] Pipeline Details - CX-2051 is a masked, conditionally activated antibody-drug conjugate (ADC) targeting epithelial cell adhesion molecule (EpCAM), with potential applications in multiple EpCAM-expressing epithelial cancers, including colorectal cancer (CRC) [3] - CX-801 is a masked interferon alpha-2b PROBODY cytokine, applicable in both immuno-oncology sensitive and insensitive tumors [3] - The company has established strategic collaborations with major oncology leaders including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Sean McCarthy, CEO and Chairman of CytomX, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 2:35 p.m. ET [1] - A live webcast of the presentation will be available on CytomX's website, and management will hold one-on-one meetings with registered investors at the conference [2]